Skip to main content

Table 1 Demographic and disease characteristics at baseline

From: Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study

Parameters

CHB group (n = 32)

Non-CHB group (n = 128)

p valuea

Matched parameters

 Female, n (%)

27 (84)

108 (84)

1.000

 Age (years)

49 (38–56)

49 (38–57)

0.964

 DAS28-CRP

4.6 (3.5–5.0)

4.6 (3.8–5.3)

0.791

Demographic characteristics

 Age of onset (years)

44 (31–52)

45 (33–53)

0.948

 Disease duration (months)

36 (9–113)

36 (12–84)

0.805

  Short duration (<6 months)

3 (9)

19 (15)

0.476

  Intermediate duration (6–24 months)

12 (38)

39 (30)

0.501

  Long duration (>24 months)

17 (53)

70 (55)

0.887

Disease characteristics

 TJC28

6 (2–10)

6 (3–10)

0.914

 SJC28

4 (1–8)

4 (2–6)

0.523

 PainVAS

4 (2–5)

4 (3–6)

0.131

 PtGA

5 (3–6)

5 (3–6)

0.355

 PrGA

5 (3–5)

5 (3–6)

0.276

 HAQ

0.6 (0–1.3)

0.6(0.1–1.2)

0.888

 CRP (mg/L)

12.1 (3.8–44.2)

12.1 (4.8–32.0)

0.543

 ESR (mm/h)

36 (20–62)

50 (24–75)

0.162

 RF positivity, n (%)

23 (72)

96 (75)

0.746

 ACPA positivity, n (%)

23 (72)

101 (79)

0.448

 SDAI

22.1 (13.6–31.3)

21.2 (14.6–29.3)

0.320

 CDAI

19 (12–28)

20 (13–26)

0.332

 RAPID3

3.3 (2.1–4.6)

3.6 (2.7–5.2)

0.128

 MMP-3 (ng/mL)

184 (86–453)

155 (86–358)

0.440

Liver function

 AST (U/L)

18 (14–25)

16 (14–21)

0.630

 ALT (U/L)

18 (12–29)

15 (10–21)

0.769

Radiographic status

 Bony erosions, n (%)

25 (78)

96 (75)

0.742

 JSN subscore

5.5 (0–18.8)

3.0 (1.0–9.8)

0.078

 JE subscore

6.0 (1.0–22.0)

4.0 (0.3–10.0)

0.009

 mTSS

11.0 (1.3–36.3)

8.0 (2.0–20.8)

0.021

Previous medications, n (%)

 Treatment-naïveb

11 (34)

55 (43)

0.431

 GCs

14 (44)

48 (38)

0.562

 MTX

16 (50)

49 (38)

0.283

 LEF

6 (19)

34 (27)

0.417

 SSZ

4 (13)

1 (1)

0.005

 HCQ

10 (31)

12 (9)

0.006

 CysA

1 (3)

5 (4)

0.853

 Biologic agents

1 (3)

3 (2)

0.821

  1. Data are presented as median (interquartile range (IQR)) or number (percentage (%))
  2. ACPA anti-cyclic citrullinated peptide antibody, ALT alanine aminotransferase, AST aspartate transaminase, CDAI Clinical Disease Activity Index, CHB chronic hepatitis B virus infection, CRP C-reactive protein, CysA cyclosporin A, DAS28 Disease Activity Score 28-joint assessment, DMARD disease-modifying anti-rheumatic drug, ESR erythrocyte sedimentation rate, GC glucocorticosteroid, HAQ Stanford Health Assessment Questionnaire, HCQ hydroxychloroquine, JE joint erosion, JSN joint space narrowing, LEF leflunomide, mTSS modified total Sharp score, MMP-3 matrix metalloproteinase-3, MTX methotrexate, NA not applicable, Pain VAS pain visual analog scale, PrGA provider global assessment of disease activity, PtGA patient global assessment of disease activity, RA rheumatoid arthritis, RAPID3 Routine Assessment of Patient Index Data 3, RF rheumatoid factor, SDAI Simplified Disease Activity Index, SJC28 28-joint swollen joint counts, SSZ sulfasalazine, TJC28 28-joint tender joint count
  3. aCompared between the CHB group and the non-CHB group using conditional logistic regression analysis: bold p values are significant
  4. bWithout glucocorticosteroid or DMARD therapy for 6 months before enrollment